Cargando…
Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer
BACKGROUND: The clinical benefit of determining the status of HER-2/neu amplification in breast cancer patients is well accepted. Although immunohistochemistry (IHC) is the most frequently used method to assess the over-expression of HER-2 protein, fluorescent in-situ hybridization (FISH) is recogni...
Autores principales: | Nistor, Andreea, Watson, Peter H, Pettigrew, Norman, Tabiti, Karim, Dawson, Angelika, Myal, Yvonne |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1382241/ https://www.ncbi.nlm.nih.gov/pubmed/16420697 http://dx.doi.org/10.1186/1472-6890-6-2 |
Ejemplares similares
-
Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry
por: ZHU, GUANG-JUN, et al.
Publicado: (2014) -
Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay
por: Goud, Kalal Iravathy, et al.
Publicado: (2012) -
Chromogenic in Situ Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma
por: Ali, Ali Hussein Mohammed, et al.
Publicado: (2019) -
HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization
por: Moelans, Cathy B., et al.
Publicado: (2009) -
Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)